

Attorney Docket No.: **PM (DC-0251)**
Inventor: **Wade and Demian**
Serial No.: **09/720,078**
Filing Date: **25 July 2001**
Page 3

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method for ~~enhancing or~~ suppressing at least the humoral immune response or CD4 Th1 immune response to a target antigen comprising administering the following:

(i) a conjugate comprising a selected antigen, which is directly or indirectly attached to an antibody that specifically binds to a molecule which is expressed by an antigen-presenting cell (APC); and

(ii) an anti-CD40 antibody, wherein the antigen-antibody conjugate of (i) and the anti-CD40 antibody of (ii) are administered simultaneously or substantially contemporaneously thereby ~~enhancing or~~ suppressing at least the humoral immune response or CD4 Th1 immune response to the target antigen when compared to the humoral immune response or CD4 Th1 immune response provided upon administration of the antigen-antibody conjugate in the absence of the anti-CD40 antibody.

Claim 2-4 (canceled)

Claim 5 (original): The method of Claim 1, which is effected *in vivo*.

Claims 6-11 (canceled).

Attorney Docket No.: **PM (DC-0251)**
Inventor: **Wade and Demian**
Serial No.: **09/720,078**
Filing Date: **25 July 2001**
Page 4

Claim 12 (original): The method according to Claim 1, wherein the antigen-antibody conjugate of (i) and the anti-CD40 antibody are administered together.

Claim 13 (original): The method according to Claim 1, wherein the antigen is directly attached to said antibody.

Claim 14 (original): The method according to Claim 13, wherein said direct attachment comprises covalent attachment of the antigen and the antibody.

Claim 15 (original): The method according to Claim 1, wherein the administered antigen-antibody conjugate of (i) and the anti-CD40 antibody are contained in the same composition.

Claim 16-30 (canceled).